Shopping Cart
- Remove All
Your shopping cart is currently empty
c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) exhibiting antitumor activity.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $2,270 | 3-6 months | |
| 50 mg | $2,980 | 3-6 months | |
| 100 mg | $4,000 | 3-6 months |
| Description | c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) exhibiting antitumor activity. |
| Targets&IC50 | c-Met:0.6 nM |
| In vitro | c-Met-IN-2 (Compound 14) exhibits weak activity on other kinases, with IC50 values of 731 nM [RON], 1075 nM [AxI], 18364 nM [VEGFR2], 2357 nM [PDGFRa], 5396 nM [c-Kit], and 17056 nM [c-Src]. |
| In vivo | In mice bearing H1993 tumors, c-Met-IN-2 (0.1, 1, 10 mg/kg, p.o., once daily) significantly reduces the volume of tumors. c-Met-IN-2 has a similar effect in SNU-5 xenograft model via oral administration at 0.3, 1 and 3 mg/kg. |
| Molecular Weight | 484.49 |
| Formula | C24H21FN10O |
| Cas No. | 1635406-73-3 |
| Relative Density. | 1.55 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.